Laboratory Model Reveals Genetic Risk Loci for AMD
|
By LabMedica International staff writers Posted on 20 May 2019 |

Image: A micrograph showing retinal cells derived from a patient\'s skin cells, via induced pluripotent stem cells. The cells are organized in a polygonal shape and have taken on characteristic pigmentation (Photo courtesy of the University of California, San Diego).
Eye disease researchers used advanced stem cell technology to create a laboratory model of age-related macular degeneration (AMD), which enabled in-depth analysis of the genetics underlying the syndrome.
AMD, one of the most common causes of vision loss in the elderly, causes the slow degradation of the cells comprising the macula of the retina, which is the region in the back of the eye that transmits information to the brain. The exact cause of the disease is unknown, but studies have suggested that genetics plays an important role.
To define the role of genetic risk in AMD, investigators at the University of California, San Diego (USA) created an in vitro model based on human induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) cells from six subjects. To do this, they generated iPSCs from skin cells, and then used a cocktail of molecules and growth factors to transform the iPSCs into retinal cells. The induced RPEs were found to have morphological and molecular characteristics similar to those of native RPE.
The model system was used to generate molecular data, including RNA transcripts and epigenetic information. These findings were combined with complementary published data from 18 adults with and without AMD.
Results revealed that the genetic variant most closely associated with AMD was rs943080, a specific genetic variation that affected expression of the VEGFA (vascular endothelial growth factor A) gene, possibly through regulation by a non-coding region of the genome. Five of the six participants had one copy of rs943080 and one person had two copies of the gene variant. VEGFA protein is known for supporting new blood vessel growth, a process that characterizes AMD.
"We did not start with the VEGFA gene when we went looking for genetic causes of AMD," said senior author Dr. Kelly A. Frazer, professor of pediatrics at the University of California, San Diego. "But we were surprised to find that, with samples from just six people, this genetic variation clearly emerged as a causal factor."
The authors concluded that their results had established a molecular hypothesis for the VEGFA genetic risk locus in AMD and illustrated the potential of iPSC-RPE as a model system to study the molecular function of genetic variation associated with AMD.
The AMD stem cell study was published in the May 9, 2019, online edition of the journal Stem Cell Reports.
Related Links:
University of California, San Diego
AMD, one of the most common causes of vision loss in the elderly, causes the slow degradation of the cells comprising the macula of the retina, which is the region in the back of the eye that transmits information to the brain. The exact cause of the disease is unknown, but studies have suggested that genetics plays an important role.
To define the role of genetic risk in AMD, investigators at the University of California, San Diego (USA) created an in vitro model based on human induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) cells from six subjects. To do this, they generated iPSCs from skin cells, and then used a cocktail of molecules and growth factors to transform the iPSCs into retinal cells. The induced RPEs were found to have morphological and molecular characteristics similar to those of native RPE.
The model system was used to generate molecular data, including RNA transcripts and epigenetic information. These findings were combined with complementary published data from 18 adults with and without AMD.
Results revealed that the genetic variant most closely associated with AMD was rs943080, a specific genetic variation that affected expression of the VEGFA (vascular endothelial growth factor A) gene, possibly through regulation by a non-coding region of the genome. Five of the six participants had one copy of rs943080 and one person had two copies of the gene variant. VEGFA protein is known for supporting new blood vessel growth, a process that characterizes AMD.
"We did not start with the VEGFA gene when we went looking for genetic causes of AMD," said senior author Dr. Kelly A. Frazer, professor of pediatrics at the University of California, San Diego. "But we were surprised to find that, with samples from just six people, this genetic variation clearly emerged as a causal factor."
The authors concluded that their results had established a molecular hypothesis for the VEGFA genetic risk locus in AMD and illustrated the potential of iPSC-RPE as a model system to study the molecular function of genetic variation associated with AMD.
The AMD stem cell study was published in the May 9, 2019, online edition of the journal Stem Cell Reports.
Related Links:
University of California, San Diego
Latest BioResearch News
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
Channels
Clinical Chemistry
view channel
Rapid Ferritin Test Enables Iron Deficiency Detection at the Point of Care
Iron deficiency is one of the world’s most common nutritional disorders and can be difficult to diagnose where access to laboratories and trained personnel is limited. Women and children in low-resource... Read more
Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40
C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read moreMolecular Diagnostics
view channel
Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
Accurately distinguishing maturity-onset diabetes of the young from type 1 diabetes is difficult in routine care, especially when onset occurs in adolescence or early adulthood. Although maturity-onset... Read more
Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
Timely cervical cancer screening prevents progression from persistent high‑risk human papillomavirus (HPV) infection, yet many adults marginalized from care do not complete routine exams.... Read more
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
Imagene AI has joined the Proscia Ready partner alliance to integrate its hematoxylin and eosin (H&E) screening tools and immunohistochemistry (IHC) image-analysis capabilities with Proscia’s Concentriq... Read more





 Assay.jpg)

